
Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.
Ebglyss showed sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W).